Thierry André is a professor of medical oncology at the Sorbonne Université in Paris and Head of the Medical Oncology Department at the Saint Antoine Hospital, Assistance Publique Hôpitaux de Paris, France, since 2011. 

Thierry André received his MD in 1991 and he was trained in medical oncology at the University of Paris. He is the President of the ARCAD foundation since 2022 (Aide et Recherche en Cancérologie Digestive). He is the Founder and was Vice President of the GERCOR Group – a multidisciplinary oncology research group – where he leads the scientific committee. He is a member of the European Society for Medical Oncology (ESMO), of the American Society of Clinical Oncology (ASCO) and of the Adjuvant Colon Cancer Endpoints (ACCENT) group. He has served on the ASCO and ESMO educational committee. He is a member of INSERM (Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Paris 75012, France). 

Thierry André’s main research interest is gastrointestinal malignancies. He is/was principal investigator of many phase 1, 2, and 3 clinical trials evaluating treatment of gastrointestinal malignancies. André’s main research interest is gastro-intestinal malignancy. Main topics of research/publications are on treatment of colorectal cancer in adjuvant and metastatic situation and gastro-intestinal cancers harboring microsatellite instability (MSI) / DNA mismatch repair deficiency (dMMR). He has published more than 500 peer-reviewed articles (H index 99; i10 index 364;   60 982 citations,  532 publications Medline).